All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Legend Biotech, Pfizer, Roche, and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
ASH 2025 | Top abstracts: What’s hot in multiple myeloma?
To help navigate the exciting content being presented at the the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.
Oral presentations: Saturday, December 6
| Abstract | Title | Presenter | Time (EST) |
| 92 | Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study | Samir Parekh | 09:45–10:00 |
| 93 | Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma | Doris Hansen | 10:00–10:15 |
| 94 | Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed/refractory multiple myeloma | Luciano Costa | 10:15–10:30 |
| 97 | Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in the AURIGA study | Alfred Chung | 09:30–09:45 |
| 99 | Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) – interim results from the randomized phase III COBRA trial | Dominik Dytfeld | 10:00–10:15 |
| 100 | Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial | Attaya Suvannasankha | 10:15–10:30 |
| 101 | Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial | Niels van de Donk | 10:30–10:45 |
| 102 | Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma | Hang Quach | 10:45–11:00 |
| 365 | Immune biomarkers of increased risk of infection in multiple myeloma (MM) | Aintzane Zabaleta | 17:00–17:15 |
| 368 | Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus Isa-Rd: 12-24-month data from the phase 3 BENEFIT trial (IFM 2020-05) | Arthur Bobin | 16:15–16:30 |
| 370 | Role of bortezomib maintenance therapy in the anti-CD38 antibody era: Interim analysis results of a randomized phase III study for transplant-ineligible newly diagnosed multiple myeloma (JCOG1911/B-DASH study) | Tomotaka Suzuki | 16:45–17:00 |
Oral presentations: Sunday, December 7
| Abstract | Title | Presenter | Time (EST) |
| 494 | Combined assessment of circulating tumor cells (CTCs) and measurable residual disease (MRD) for dynamic risk assessment of patients (Pts) with multiple myeloma (MM) | Bruno Paiva | 09:45–10:00 |
| 578 | Ending the undetermined significance of monoclonal gammopathies (MGUS): First results of the NoMoreMGUS study | Bruno Paiva | 12:15–12:30 |
| 698 | Efficacy and safety of talquetamab + teclistamab in patients with relapsed/refractory multiple myeloma and extramedullary disease: Updated phase 2 results from the RedirecTT-1 study with extended follow-up | Saad Usmani | 16:45–17:00 |
| 701 | Safety and efficacy of talquetamab + teclistamab in patients with relapsed/refractory multiple myeloma from phase 1b of RedirecTT-1: Results with an extended median follow-up of 3 years | María-Victoria Mateos | 17:30–17:45 |
Oral presentations: Monday, December 8
| Abstract | Title | Presenter | Time (EST) |
| 916 | S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in multiple myeloma | Adolfo Aleman | 15:30–15:45 |
| 1033 | The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial | Lauren Merz | 16:30–16:45 |
| 1034 | Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality | Surbhi Sidana | 16:45–17:00
|
| 1035 | Outcomes of stem cell boost (SCB) versus supportive care alone for prolonged cytopenias after chimeric antigen receptor T cell therapy (CAR-T) in relapsed/refractory multiple myeloma (RRMM): A multi-center real-world analysis | Cindy Varga | 17:00–17:15
|
| 1037 | Redefining function high-risk (FHR) multiple myeloma (MM) in the context of upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT) | Luciano Costa | 17:30–17:45
|
Oral presentations: Tuesday, December 9
| Abstract | Title | Presenter | Time (EST) |
| LBA-1 | Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): Preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010 | Phoebe Joy Ho | 07:30–07:45 |
| LBA-6 | Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (pts) with relapsed refractory multiple myeloma (RRMM): Results of MajesTEC-3 | María-Victoria Mateos | 08:45–09:00 |
Posters
| Abstract | Title | Presenter | Date and time (EST) |
| 2253 | A clinical overview of infection in patients receiving elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) for newly diagnosed multiple myeloma in the MagnetisMM-6 trial | Ja Min Byun | Saturday, December 6, 17:30–19:30 |
| 2258 | Randomized comparison between isatuximab-Rd versus Rd induction, followed by isa-R versus R maintenance in very elderly patients with NDMM: Efficacy data on MRD after induction (AGMT-MM04 Trial) |
Heinz Ludwig | Saturday, December 6, 17:30–19:30 |
| 2262 | Long-term responders from the phase 3 DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma | Vania Hungria | Saturday, December 6, 17:30–19:30 |
| 2263 | Health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation and treated with isatuximab, lenalidomide, bortezomib, and dexamethasone (Isa-RVd) versus RVd alone: Results from Part 1 of the GMMG-HD7 study |
Elias K. Mai | Saturday, December 6, 17:30–19:30 |
| 2264 | Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study | Suzanne Trudel | Saturday, December 6, 17:30–19:30
|
| 2265 | Patients with relapsed/refractory multiple myeloma who achieved sustained minimal residual disease negativity in the DREAMM-7 trial | María-Victoria Mateos | Saturday, December 6, 17:30–19:30
|
| 4069 | Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations | Saurabh Zanwar | Sunday, December 7, 18:00–20:00 |
| 4029 | Health-related quality of life with belantamab mafodotin in patients with relapsed or refractory multiple myeloma (RRMM): An exploratory analysis of overall quality of life in DREAMM-7 | Sagar Lonial | Sunday, December 7, 18:00–20:00
|
| 4039 | Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND) | Matthew Rees | Sunday, December 7, 18:00–20:00 |
| 4044 | Home administration of isatuximab subcutaneous by on-body injector in relapsed/refractory multiple myeloma in the phase 3 IRAKLIA study | María-Victoria Mateos | Sunday, December 7, 18:00–20:00 |
| 5820 | Functional high-risk relapsed/refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): DREAMM-7 and DREAMM-8 subgroup analysis | María-Victoria Mateos | Monday, December 8, 18:00–20:00 |
| 5823 | Patient-reported outcomes from DREAMM-7 and DREAMM-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change | Suzanne Trudel | Monday, December 8, 18:00–20:00 |
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content